Bioindustry Park Silvano Fumero

Code Ocean Honored by the 2023 BioTech Breakthrough Awards

Retrieved on: 
Thursday, November 9, 2023
Cloud, Research, Creativity, Therapy, Sutro Biopharma, Biotechnology, Science, Capsule, Automation, Software, Bioindustry Park Silvano Fumero, API, Knowledge, Environment, Online shopping, Immunology, Ocean, Genomics

NEW YORK, Nov. 9, 2023 /PRNewswire-PRWeb/ -- Code Ocean, the world's first Reproducible Research Cloud, today announced that it has been selected as a winner of the 2023 BioTech Breakthrough Awards in the category of "QC Data Management Solution of the Year."

Key Points: 
  • NEW YORK, Nov. 9, 2023 /PRNewswire-PRWeb/ -- Code Ocean , the world's first Reproducible Research Cloud, today announced that it has been selected as a winner of the 2023 BioTech Breakthrough Awards in the category of "QC Data Management Solution of the Year."
  • Code Ocean provides the first and only integrated library and workbench that guarantees reproducibility and speeds up discovery for life sciences, pharmaceutical, and biotech researchers.
  • The Code Ocean digital lab provides a central place for researchers to share data and computational assets, and collaborate more quickly and effectively.
  • Code Ocean preserves a record of all coding, data and software, maintaining complete visibility, lineage, and reproducibility.

STEMconnector Releases New Ebook on Bioindustrial Manufacturing

Retrieved on: 
Wednesday, March 22, 2023
University of California, Davis, Twist Bioscience, Education, Bioindustry Park Silvano Fumero, Biotechnology, Science, technology, engineering, and mathematics, Student, UC, Manufacturing USA, STEM, Growth, Synthetic biology, Book, Management, Science, Engineering

LOS ANGELES, March 22, 2023 /PRNewswire/ -- STEMconnector released its latest ebook, entitled Bioindustrial Manufacturing, Made in the USA, aimed at informing and inspiring more students to pursue pathways in Science, Technology, Engineering, and Math (STEM). Production of the ebook, which is focused on bioindustrial manufacturing career pathways, was funded by BioMADE.

Key Points: 
  • Production of the ebook, which is focused on bioindustrial manufacturing career pathways, was funded by BioMADE.
  • Aimed at engaging middle school through post-secondary students and educators, Bioindustrial Manufacturing, Made in the USA was designed to educate, inform, and inspire the next-generation workforce to pursue STEM pathways in advanced bioindustrial manufacturing.
  • "Bioindustrial manufacturing is growing rapidly in response to increasing innovations generated from the biotech sector, driving increased demand for a diverse STEM-skilled workforce," said Dr. Jo Webber, CEO of STEMconnector.
  • Ebook readers can access many resources throughout the pages of Bioindustrial Manufacturing, Made in the USA, including different types of teacher programs, internships, apprenticeships, community, and university programs.

EQS-News: BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting

Retrieved on: 
Monday, February 27, 2023
EBITDA, Genomics, M-Brain Group, BioScience, Psicose, BRAIN, Acquisition, Investment, Growth, Enzyme, MP, CFO, Bioindustry Park Silvano Fumero, Sugar, Pharmaceutical industry, Video game, Fine chemical

BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting

Key Points: 
  • BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting
    The issuer is solely responsible for the content of this announcement.
  • BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting
    Zwingenberg, Germany, 27.
  • February 2023 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, had a strong start into the fiscal year with very satisfying revenue growth in both divisions.
  • Adriaan Moelker, CEO BRAIN Biotech AG, states: “BRAIN continues well on its path of profitable growth.

EQS-News: BRAIN Biotech AG reports record figures in fiscal year 2021/22 − despite challenging geopolitical environment

Retrieved on: 
Thursday, February 2, 2023
Genome, EBITDA, R, Tax, BRAIN, Bioindustry Park Silvano Fumero, M-Brain Group, Environment, BioScience, Genomics, Growth, Federal Executive Boards, Research, Enzyme, Depreciation, EUR, Acquisition, Investment, Animal, Fine chemical

Zwingenberg, January 16, 2023 – BRAIN Biotech, a leading provider of solutions for the biologization of industry, today presented its Annual Report 2021/22.

Key Points: 
  • Zwingenberg, January 16, 2023 – BRAIN Biotech, a leading provider of solutions for the biologization of industry, today presented its Annual Report 2021/22.
  • Adriaan Moelker, CEO of BRAIN Biotech AG: "The 2021/22 financial year was characterized by various geopolitical crises and the continuing effects of the pandemic situation.
  • I am very proud to be able to present a record year in this challenging environment and would like to expressly thank all our employees for their outstanding personal commitment."
  • Biotechnological research and the development of biotechnological processes and products build the basis of the business activities of the BRAIN Biotech Group.

Calyxt Joins Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense Initiative, to Advance Sustainable Plant-Based Biomanufacturing

Retrieved on: 
Tuesday, November 1, 2022
Growth, Annual report, Risk, National Biotechnology Research Park, Knowledge, SEC, Organization, Research, 8-K, Ecosystem, Department, Synthetic biology, White House, Bioindustry Park Silvano Fumero, Government, STEM, University, Education, NASDAQ, Private Securities Litigation Reform Act, Company, Biofactories, Communication, Department of Defence, Carbon, White, Engineering, Forward-looking statement, Defense, Pharmaceutical industry, Renewable energy, Management

ROSEVILLE, Minn., Nov. 1, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company, announced today that it has become a member of Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense initiated Manufacturing Innovation Institute dedicated to advancing bioindustrial manufacturing across the nation.

Key Points: 
  • Calyxt intends to work with BioMADE and its nationwide roster of collaborating organizations toward BioMADE's goal of securing America's future through bioindustrial manufacturing innovation, education and collaboration.
  • "The bioindustrial manufacturing and broader bioeconomy ecosystem is poised for significant growth, and by joining BioMADE we are positioning Calyxt to be part of that growth."
  • "BioMADE is excited to welcome Calyxt into its select membership network," said BioMADE Chief Technology Officer Melanie Tomczak.
  • "Calyxt's strength and knowledge in engineering sustainable plant-based solutions will bring important experience and expertise to the BioMADE community, as we collectively build the American bioindustrial manufacturing ecosystem.

DGAP-News: BRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting

Retrieved on: 
Monday, August 29, 2022
M-Brain Group, Enzyme, CEO, Technology, Sustainability, Agriculture, EBITDA, Genome editing, Risk assessment, R, Board, Supervisory board, BRAIN, Bioindustry Park Silvano Fumero, Investment, Goal, Genome, CFO, Acceleration, Pharmacology, BEC, CRISPR, Sustainability reporting, ESG, BioScience, Fermentation, BMC, Acquisition, Growth, Annual, Mobile phone, Video game, Lithium, Fine chemical, Renewable energy

BRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting

Key Points: 
  • BRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting
    The issuer is solely responsible for the content of this announcement.
  • BRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting
    Zwingenberg, Germany, August 29th, 2022 BRAIN Biotech AG today published its 9M 2021/22 results.
  • Directors Dealing: Adriaan Moelker, BRAIN Biotech CEO, has privately acquired an additional 5,000 shares of BRAIN Biotech AG at 8.70 / share.
  • Lukas Linnig, CFO BRAIN Biotech, has privately acquired an additional 5,000 shares of BRAIN Biotech AG at 8.895 / share.

DGAP-News: BRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting

Retrieved on: 
Monday, May 30, 2022
European Patent Office, Genome, EPO, R, EBITDA, BEC, PCT, EUR, Investment, Ivar Formo, BioScience, Bioindustry Park Silvano Fumero, Patent, Genome editing, M-Brain Group, CRISPR, Technology, Enzyme, Calendar, BMC, Acquisition, CFO, European Patent Convention, BRAIN, CEO, Fermentation, Video game, Fine chemical

BRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting

Key Points: 
  • BRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting
    The issuer is solely responsible for the content of this announcement.
  • BRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting
    Full fiscal year guidance now includes Breatec B.V.
    Zwingenberg, Germany, May 30th, 2022 BRAIN Biotech AG today published its half year results, 6M 2021/22.
  • Adjusted EBITDA strongly increased from -3.4 million to -2.4 million despite ongoing investments into BRAIN Biotech AGs CRISPR platform business of 1.0 million in the reporting period.
  • Lukas Linnig, CFO at BRAIN Biotech AG, states: It makes me very proud to see BRAIN back on the growth path.

DGAP-News: BRAIN Biotech AG: Very Dynamic Start into the Fiscal Year 2021/22, 3M Reporting

Retrieved on: 
Wednesday, February 23, 2022
BRAIN, European Patent Office, Growth, Fiscal, Investment, European Patent Convention, CRISPR, Bioindustry Park Silvano Fumero, CFO, Genome, BMC, BioScience, Acquisition, Genome editing, DNA, GBP, Technology, M-Brain Group, Economic development, Goal, CEO, Research, BEC, EBITDA, Ridesharing company, Security (finance), Fine chemical, Video game

BRAIN Biotech AG: Very Dynamic Start into the Fiscal Year 2021/22, 3M Reporting

Key Points: 
  • BRAIN Biotech AG: Very Dynamic Start into the Fiscal Year 2021/22, 3M Reporting
    The issuer is solely responsible for the content of this announcement.
  • BRAIN Biotech AG: Very Dynamic Start into the Fiscal Year 2021/22, 3M Reporting
    BRAIN Biotech AG today published its first quarter results, 3M 2021/22.
  • The group had a very strong start into the fiscal year with dynamic revenue growth in both divisions, positive operating leverage and a solid financial position.
  • Adriaan Moelker, CEO BRAIN Biotech AG states: "The positive operating trend from the fourth quarter has strongly extended to the start of the new fiscal year.

BioMADE Announces $12.1 Million to 16 Projects to Accelerate Bioindustrial Manufacturing in the United States

Retrieved on: 
Wednesday, February 9, 2022
Research, Other Defense, Contracts, Training, Defense, University, Other Manufacturing, Education, Packaging, Science, Chemicals, Plastics, Manufacturing, Carbon, Knowledge, Mark (given name), Policy, Emerging technologies, Industry, Direct, Southern Illinois University Edwardsville, Machine learning, Molecular biology, Level, DIY, Polybutylene succinate, Succinic acid, Organic acid, Nanoparticle, Setup, Chicken, Awareness, Innovation, Chlorogenate—glucarate O-hydroxycinnamoyltransferase, National Corn Growers Association, Student, Program, Bacteria, Technology, Polyester, U.S. Department of Defense Strategy for Operating in Cyberspace, University, Workforce, Security, Fermentation, DNA, Competition (economics), Bioindustry Park Silvano Fumero, Farmer, STEM, Optical comparator, National, Ecosystem, Biology, Skill, Industrial production, Education, Polymer, Current, Renewable energy, Fine chemical, Management, Agility, Trust

BioMADE, the Bioindustrial Manufacturing and Design Ecosystem, is awarding $5.8 million in federal funds to 16 innovative projects aimed at accelerating bioindustrial manufacturing knowledge, capabilities, and workforce in the U.S.

Key Points: 
  • BioMADE, the Bioindustrial Manufacturing and Design Ecosystem, is awarding $5.8 million in federal funds to 16 innovative projects aimed at accelerating bioindustrial manufacturing knowledge, capabilities, and workforce in the U.S.
  • These projects will leverage an additional $6.3 million in non-federal cost share, providing a significant boost to the ecosystem.
  • Were extremely pleased to announce these projects, which represent all areas of our mission, said Douglas Friedman, BioMADE CEO.
  • The partnerships created through these projects highlight how BioMADE brings together a diverse, growing industry to reach shared goals.

DGAP-News: BRAIN Group significantly expands its food enzyme business with the acquisition of Breatec B.V. and Comix business

Retrieved on: 
Tuesday, February 1, 2022
CEO, Food, Fermentation, M-Brain Group, Philosophy, MD, Vitamin, Calendar, United Nations Global Compact, Underground comix, ISIN, Technology, Environment, BRAIN, EMEA, UN, Bioindustry Park Silvano Fumero, Enzyme, Health, Frankfurt Stock Exchange, Acquisition, EUR, IPO, EBITDA, FSSC, Achievement, Flour, Industry, Participation, RSPO, Organic, Solution, Machine, Security (finance), Fine chemical, Breatec, Comix, BRAIN, BREATEC, COMIX, BRAIN

BRAIN Group significantly expands its food enzyme business with the acquisition of Breatec B.V. and Comix business

Key Points: 
  • BRAIN Group significantly expands its food enzyme business with the acquisition of Breatec B.V. and Comix business
    The issuer is solely responsible for the content of this announcement.
  • BRAIN Group significantly expands its food enzyme business with the acquisition of Breatec B.V. and Comix business
    Today, BRAIN Biotech AG announced that it has acquired Breatec B.V. including the Comix business, Nieuwkuijk, Netherlands, a successful distributor, formulator and blender of functional food ingredients for the baking and milling industry.
  • Adriaan Moelker, CEO BRAIN AG, expresses: "We are very glad to welcome the Breatec and Comix team as a new BRAIN Group member.
  • I am really looking forward to personally accelerate the integration of the Breatec and Comix team into the BRAIN Group."